The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders

Modafinil (MOD) and its R-enantiomer, armodafinil, are FDA-approved medications primarily used to treat narcolepsy and other sleep-related disorders. Beyond these indications, they have gained significant attention as off-label cognitive enhancers. This review examines the neurobiological mechanisms of modafinil, its potential as a therapeutic agent for substance use disorders, and the reasons behind its unique profile compared to conventional psychostimulants like cocaine or amphetamines.

Modafinil’s primary mechanism of action involves the inhibition of the dopamine transporter (DAT), which increases extracellular dopamine levels in key brain regions associated with cognitive function, such as the prefrontal cortex and nucleus accumbens. Unlike traditional psychostimulants, modafinil does not appear to directly stimulate dopamine release. Instead, it modulates a complex array of neurotransmitter systems, including norepinephrine, glutamate, GABA, histamine, and orexin. Notably, modafinil has been shown to increase electrical coupling between neurons, which may contribute to its wake-promoting and pro-cognitive effects without the broad, non-selective activation patterns typical of amphetamines.

Substance use disorders are frequently accompanied by cognitive deficits that hinder treatment success. Modafinil is being investigated as an adjunct therapy to improve cognitive function and reduce drug-seeking behavior. Its appeal lies in its low abuse liability, which is attributed to its specific chemical structure, poor water solubility, and unique pattern of brain activation. While some clinical trials have shown promising trends in reducing cocaine and methamphetamine use, results remain mixed. The drug appears to be well-tolerated, but its success in clinical settings may depend on patient-specific factors and the integration of behavioral therapies.